Informative censoring occurs when progression-free survival is the primary end point of a randomized clinical trial and unequal patient dropout is observed between treatment arms owing to

poorer tolerance of experimental treatment. Herein we discuss how informative censoring in the experimental arm before criteria for disease progression are met causes bias towards a positive

result. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution RELEVANT ARTICLES Open Access articles citing this article. *

FIRST-LINE OXALIPLATIN-BASED CHEMOTHERAPY AND NIVOLUMAB FOR METASTATIC MICROSATELLITE-STABLE COLORECTAL CANCER—THE RANDOMISED METIMMOX TRIAL * Anne Hansen Ree * , Jūratė Šaltytė Benth *  … 

Shuai Wang * , Robert Frederich *  & James P. Mancuso _Therapeutic Innovation & Regulatory Science_ Open Access 07 October 2023 ACCESS OPTIONS Access through your institution Access

Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print

issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to

local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES *

Ranganathan, P. & Pramesh, C. S. Censoring in survival analysis: potential for bias. _Perspect. Clin. Res._ 3, 40 (2012). Article  Google Scholar  * Stone, A. M. et al. Research outcomes

and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. _Eur. J. Cancer_ 47, 1763–1771 (2011). Article  CAS  Google Scholar  * Fleming,

T. R., Rothmann, M. D. & Lu, H. L. Issues in using progression-free survival when evaluating oncology products. _J. Clin. Oncol._ 27, 2874–2880 (2009). Article  Google Scholar  * Shih,

W. Problems in dealing with missing data and informative censoring in clinical trials. _Curr. Control Trials Cardiovasc. Med._ 3, 4 (2002). Article  Google Scholar  * Baselga, J. et al.

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. _N. Engl. J. Med._ 366, 520–529 (2012). Article  CAS  Google Scholar  * Piccart, M. et al. Everolimus plus

exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. _Ann. Oncol._ 25, 2357–2362

(2014). Article  CAS  Google Scholar  * Templeton, A. J. et al. Influence of censoring on conclusions of trials for women with metastatic breast cancer. _Eur. J. Cancer_ 51, 721–724 (2015).

Article  Google Scholar  * Sun, J. _The Statistical Analysis of Interval-Censored Failure Time Data: Statistics for Biology and Health_. (Springer, 2006). * Sparano, J. A. et al. Adjuvant

chemotherapy guided by a 21-gene expression assay in breast cancer. _N. Engl. J. Med._ 379, 111–121 (2018). Article  CAS  Google Scholar  * Ethier, J.L. et al. Influence of competing risks

of death on the interpretation of adjuvant endocrine therapy trials for breast cancer. _Cancer Res_. 79, Abstract P4-14-03 (2019). Download references AUTHOR INFORMATION AUTHORS AND

AFFILIATIONS * Department of Oncology, St. Claraspital Basel, University of Basel, Basel, Switzerland Arnoud J. Templeton * Faculty of Medicine, University of Basel, Basel, Switzerland

Arnoud J. Templeton * Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada Eitan Amir & Ian F. Tannock Authors

* Arnoud J. Templeton View author publications You can also search for this author inPubMed Google Scholar * Eitan Amir View author publications You can also search for this author inPubMed 

Google Scholar * Ian F. Tannock View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Ian F. Tannock. ETHICS

DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. SUPPLEMENTARY INFORMATION SUPPLEMENTARY TABLE 1 RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS

ARTICLE CITE THIS ARTICLE Templeton, A.J., Amir, E. & Tannock, I.F. Informative censoring — a neglected cause of bias in oncology trials. _Nat Rev Clin Oncol_ 17, 327–328 (2020).

https://doi.org/10.1038/s41571-020-0368-0 Download citation * Published: 09 April 2020 * Issue Date: June 2020 * DOI: https://doi.org/10.1038/s41571-020-0368-0 SHARE THIS ARTICLE Anyone you

share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative